## Donald A Barkauskas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3515678/publications.pdf

Version: 2024-02-01

201674 123424 4,011 67 27 61 citations h-index g-index papers 68 68 68 8461 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. American Journal of Pathology, 2022, 192, 917-925.	3.8	10
2	Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912.	1.6	O
3	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO Precision Oncology, 2021, 5, 75-87.	3.0	27
4	Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma, 2021, 2021, 1-10.	1.3	6
5	Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood, 2021, 137, 3595-3603.	1.4	40
6	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular Cancer Therapeutics, 2021, 20, 1072-1079.	4.1	6
7	STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. European Journal of Cancer, 2021, 148, 215-229.	2.8	24
8	Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. Cancer Chemotherapy and Pharmacology, 2021, 88, 359-365.	2.3	7
9	Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622) Journal of Clinical Oncology, 2021, 39, 10010-10010.	1.6	10
10	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	1.6	101
11	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2021, 39, 3716-3724.	1.6	18
12	<b>Germline Cancer Predisposition Variants in</b> â€, <b>Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group</b> . Journal of the National Cancer Institute, 2021, 113, 875-883.	6.3	55
13	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. Blood, 2021, 138, 3679-3679.	1.4	4
14	Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‣1 expression in cancer patients. International Journal of Cancer, 2020, 146, 3087-3097.	5.1	20
15	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	4.1	14
16	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncolmmunology, 2020, 9, 1781997.	4.6	8
17	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Na $ ilde{A}^-$ ve Patients with Diverse Cancers. Molecular Cancer Therapeutics, 2020, 19, 2139-2145.	4.1	50
18	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	4.1	17

#	Article	IF	Citations
19	Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. New England Journal of Medicine, 2020, 382, 2207-2219.	27.0	157
20	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
21	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncolmmunology, 2020, 9, 1710052.	4.6	17
22	Rhabdomyosarcoma Histology Classification using Ensemble of Deep Learning Networks., 2020,,.		2
23	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research, 2019, 25, 3229-3238.	7.0	61
24	Relations of combat stress and posttraumatic stress disorder to 24-h plasma and cerebrospinal fluid interleukin-6 levels and circadian rhythmicity. Psychoneuroendocrinology, 2019, 100, 237-245.	2.7	24
25	Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2019, 66, e27444.	1.5	33
26	Genomeâ€wide association study identifies the <i>GLDC</i> /i>/ <i>IL33</i> locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
27	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. Journal of Clinical Oncology, 2018, 36, 3466-3476.	1.6	21
28	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. British Journal of Cancer, 2018, 119, 615-621.	6.4	83
29	Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1. Blood, 2018, 132, 1625-1625.	1.4	2
30	Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children's Oncology Group, the Children's Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute Journal of Clinical Oncology, 2018, 36, 10515-10515.	1.6	9
31	Can DNA methylation patterns be used as predictive biomarkers for chemotherapy response in osteosarcoma?. Journal of Clinical Oncology, 2018, 36, 11525-11525.	1.6	O
32	The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma. Pediatric Blood and Cancer, 2017, 64, e26659.	1.5	3
33	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clinical Cancer Research, 2017, 23, 4242-4250.	7.0	704
34	A novel prognostic model for osteosarcoma using circulating <scp>CXCL</scp> 10 and <scp>FLT</scp> 3 <scp>LG</scp> . Cancer, 2017, 123, 144-154.	4.1	26
35	Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS ONE, 2017, 12, e0181204.	2.5	8
36	Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget, 2017, 8, 96738-96752.	1.8	41

#	Article	IF	CITATIONS
37	Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body Journal of Clinical Oncology, 2017, 35, 10519-10519.	1.6	0
38	Prospective Associations Between Traumatic Brain Injury and Postdeployment Tinnitus in Active-Duty Marines. Journal of Head Trauma Rehabilitation, 2016, 31, 30-39.	1.7	14
39	p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma. Cancer Research, 2016, 76, 4002-4011.	0.9	27
40	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 3643-3650.	7.0	23
41	Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen Journal of Clinical Oncology, 2016, 34, 10507-10507.	1.6	62
42	Crossâ€species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Medicine, 2015, 4, 977-988.	2.8	69
43	Gene expression profiling of <scp>E</scp> wing sarcoma tumours reveals the prognostic importance of tumourâ€"stromal interactions: a report from the <scp>C</scp> hildren's <scp>O</scp> ncology <scp>G</scp> roup. Journal of Pathology: Clinical Research, 2015, 1, 83-94.	3.0	66
44	The serum immunoglobulin G glycosylation signature of gastric cancer. EuPA Open Proteomics, 2015, 6, 1-9.	2.5	45
45	Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics, 2015, 10, 31-39.	2.7	26
46	Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival. Cancer, 2015, 121, 697-707.	4.1	19
47	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
48	Meta-analysis of effects of demographic and treatment variables on outcome for localized paratesticular rhabdomyosarcoma (PT RMS) in North America and Europe Journal of Clinical Oncology, 2015, 33, 10044-10044.	1.6	0
49	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
50	Assessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk. JAMA Psychiatry, 2014, 71, 423.	11.0	290
51	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatric Blood and Cancer, 2014, 61, 1558-1564.	1.5	23
52	Serum Glycan Signatures of Gastric Cancer. Cancer Prevention Research, 2014, 7, 226-235.	1.5	48
53	The cumulative effect of different childhood trauma types on self-reported symptoms of adult male depression and PTSD, substance abuse and health-related quality of life in a large active-duty military cohort. Journal of Psychiatric Research, 2014, 58, 46-54.	3.1	105
54	Analysis of serum insulin growth factorâ€1 concentrations in localized osteosarcoma: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 749-752.	1.5	9

#	Article	IF	Citations
55	Circadian rhythmicity, variability and correlation of interleukin-6 levels in plasma and cerebrospinal fluid of healthy men. Psychoneuroendocrinology, 2014, 44, 71-82.	2.7	52
56	Association Between Traumatic Brain Injury and Risk of Posttraumatic Stress Disorder in Active-Duty Marines. JAMA Psychiatry, 2014, 71, 149.	11.0	181
57	Stress-Induced Isoforms of MDM2 and MDM4 Correlate with High-Grade Disease and an Altered Splicing Network in Pediatric Rhabdomyosarcoma. Neoplasia, 2013, 15, 1049-IN8.	5.3	19
58	Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics, 2013, 45, 799-803.	21.4	181
59	Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology, 2013, 38, 2378-2382.	2.7	27
60	High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2013, 60, 2042-2046.	1.5	32
61	The Children's Oncology Group and QuadW Foundation osteosarcoma banking experience Journal of Clinical Oncology, 2013, 31, 10053-10053.	1.6	0
62	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
63	Outcome for adolescent and young adult patients with osteosarcoma. Cancer, 2012, 118, 4597-4605.	4.1	153
64	Investigation of the insulinâ€like growth factorâ€1 signaling pathway in localized Ewing sarcoma. Cancer, 2011, 117, 4966-4976.	4.1	21
65	A general-purpose baseline estimation algorithm for spectroscopic data. Analytica Chimica Acta, 2010, 657, 191-197.	5.4	18
66	Analysis of MALDI FT-ICR mass spectrometry data: A time series approach. Analytica Chimica Acta, 2009, 648, 207-214.	5.4	13
67	Centralizers in graph products of groups. Journal of Algebra, 2007, 312, 9-32.	0.7	10